These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29040318)

  • 1. Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
    Burchill MA; Roby JA; Crochet N; Wind-Rotolo M; Stone AE; Edwards MG; Dran RJ; Kriss MS; Gale M; Rosen HR
    PLoS One; 2017; 12(10):e0186213. PubMed ID: 29040318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals.
    Burchill MA; Golden-Mason L; Wind-Rotolo M; Rosen HR
    J Viral Hepat; 2015 Dec; 22(12):983-91. PubMed ID: 26482547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies.
    Yoneyama H; Morishita A; Iwama H; Fujita K; Masaki T; Tani J; Tadokoro T; Nomura T; Sakamoto T; Oura K; Takuma K; Nakahara M; Mimura S; Deguchi A; Oryu M; Tsutsui K; Himoto T; Shimotohno K; Wakita T; Kobara H; Masaki T
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1126-1135. PubMed ID: 32839985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
    Teraoka Y; Uchida T; Imamura M; Hiraga N; Osawa M; Kan H; Saito Y; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    J Gen Virol; 2018 Aug; 99(8):1058-1065. PubMed ID: 29916799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
    Takaguchi K; Toyoda H; Tsutsui A; Suzuki Y; Nakamuta M; Imamura M; Senoh T; Nagano T; Tada T; Tachi Y; Hiraoka A; Michitaka K; Shibata H; Joko K; Okubo H; Tsuji K; Takaki S; Watanabe T; Ogawa C; Chayama K; Kumada T; Kudo M; Kumada H
    J Gastroenterol; 2019 Aug; 54(8):742-751. PubMed ID: 30848363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.
    Iio E; Shimada N; Abe H; Atsukawa M; Yoshizawa K; Takaguchi K; Eguchi Y; Nomura H; Kuramitsu T; Kang JH; Matsui T; Hirashima N; Tsubota A; Kusakabe A; Hasegawa I; Miyaki T; Shinkai N; Fujiwara K; Nojiri S; Tanaka Y
    J Gastroenterol; 2017 Jan; 52(1):94-103. PubMed ID: 27236547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b.
    Chida T; Kawata K; Ohta K; Matsunaga E; Ito J; Shimoyama S; Yamazaki S; Noritake H; Suzuki T; Suda T; Kobayashi Y
    Gut Liver; 2018 Mar; 12(2):201-207. PubMed ID: 29212314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
    Suda G; Furusyo N; Toyoda H; Kawakami Y; Ikeda H; Suzuki M; Arataki K; Mori N; Tsuji K; Katamura Y; Takaguchi K; Ishikawa T; Tsuji K; Shimada N; Hiraoka A; Yamsaki S; Nakai M; Sho T; Morikawa K; Ogawa K; Kudo M; Nagasaka A; Furuya K; Yamamoto Y; Kato K; Ueno Y; Iio E; Tanaka Y; Kurosaki M; Kumada T; Chayama K; Sakamoto N
    J Gastroenterol; 2018 Jan; 53(1):119-128. PubMed ID: 28560477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis.
    Lee BS; Song MJ; Kwon JH; Lee TH; Jang JW; Kim SH; Lee SH; Kim HS; Kim JH; Kim SB; Ko SY; Song DS
    Gut Liver; 2019 Mar; 13(2):191-196. PubMed ID: 30400729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral Expression of
    Afzal M; Ali A; Sheikh N; Rafique S; Idrees M
    J Interferon Cytokine Res; 2020 Jun; 40(6):301-309. PubMed ID: 32486887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
    Zappulo E; Scotto R; Buonomo AR; Maraolo AE; Pinchera B; Gentile I
    Expert Opin Pharmacother; 2020 Feb; 21(3):261-273. PubMed ID: 31914336
    [No Abstract]   [Full Text] [Related]  

  • 12. Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients.
    Ueno T; Osawa M; Shiozaki T; Green M; Garimella T
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):903-913. PubMed ID: 30667592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety Exposure-Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Subjects.
    Osawa M; Ueno T; Shiozaki T; Li H; Garimella T
    J Clin Pharmacol; 2019 Apr; 59(4):557-565. PubMed ID: 30566237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
    Poordad F; Sievert W; Mollison L; Bennett M; Tse E; Bräu N; Levin J; Sepe T; Lee SS; Angus P; Conway B; Pol S; Boyer N; Bronowicki JP; Jacobson I; Muir AJ; Reddy KR; Tam E; Ortiz-Lasanta G; de Lédinghen V; Sulkowski M; Boparai N; McPhee F; Hughes E; Swenson ES; Yin PD;
    JAMA; 2015 May; 313(17):1728-35. PubMed ID: 25942723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
    Muir AJ; Poordad F; Lalezari J; Everson G; Dore GJ; Herring R; Sheikh A; Kwo P; Hézode C; Pockros PJ; Tran A; Yozviak J; Reau N; Ramji A; Stuart K; Thompson AJ; Vierling J; Freilich B; Cooper J; Ghesquiere W; Yang R; McPhee F; Hughes EA; Swenson ES; Yin PD
    JAMA; 2015 May; 313(17):1736-44. PubMed ID: 25942724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
    Akuta N; Toyota J; Karino Y; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; McPhee F; Noviello S; Kumada H
    J Gastroenterol; 2018 Sep; 53(9):1089-1097. PubMed ID: 29500489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    Suda G; Ogawa K; Yamamoto Y; Katagiri M; Furuya K; Kumagai K; Konno J; Kimura M; Kawagishi N; Ohara M; Umemura M; Ito J; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Tsubota A; Shimada N; Iio E; Tanaka Y; Sakamoto N;
    J Gastroenterol; 2017 Oct; 52(10):1122-1129. PubMed ID: 28315983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.
    Thiam A; Conway B
    Drugs Today (Barc); 2018 Apr; 54(4):237-244. PubMed ID: 29869645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.
    Hassanein T; Sims KD; Bennett M; Gitlin N; Lawitz E; Nguyen T; Webster L; Younossi Z; Schwartz H; Thuluvath PJ; Zhou H; Rege B; McPhee F; Zhou N; Wind-Rotolo M; Chung E; Griffies A; Grasela DM; Gardiner DF
    J Hepatol; 2015 May; 62(5):1204-6. PubMed ID: 25559328
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.